March 10, 2026 As GLP-1 indications expand, accurate risk assessment depends on confirming diagnosis, companion therapy signals, and persistence in Prescription Data
The surging demandand high costof GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, originally developed for diabetes but now widely used for weight loss, presents a complex balancing act for insurers to control near-term drug costs and manage long-term health outcomes
However, compounded GLP-1s are not FDA-approved and, as a result, come with a level of risk
We understand how discouraging that can be
Given the 5 to 8 minute plasma half-life, protocols that use subcutaneous injection are working against basic pharmacokinetics
Our providers listen first, then help you find a path that works, whether thats injectable GLP-1s now or oral options as they become available through our programs